NCT01453283View on ClinicalTrials.gov

Tabectedin to Treat Children and Adolescents With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 20, 2006

Primary Completion Date

October 11, 2011

Study Completion Date

October 11, 2011

Conditions
Solid Tumors
Interventions
DRUG

Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01453283 - Tabectedin to Treat Children and Adolescents With Cancer | Biotech Hunter | Biotech Hunter